Functional impairment of activated protein C in breast cancer - relationship to survival outcomes.

Mario Roselli(University of Rome Tor Vergata), Fiorella Guadagni(Vita-Salute San Raffaele University), Jhessica Alessandroni(University of Rome Tor Vergata), Renato Massoud(University of Rome Tor Vergata), Patrizia Ferroni(Istituti di Ricovero e Cura a Carattere Scientifico), Cristiano Ialongo(University of Rome Tor Vergata), Sabrina Mariotti(Istituto Superiore di Sanità), Francesco Cavaliere, Ilaria Portarena, Silvia Riondino(Sapienza University of Rome), Leopoldo Costarelli(Azienda Ospedaliera San Giovanni Addolorata), Sergio Bernardini(University of Rome Tor Vergata)
PubMed
January 1, 2016
Cited by 2

Related Papers

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
|Alzheimer s & Dementia|2011|412
CSF biomarker variability in the Alzheimer's Association quality control program
|Alzheimer s & Dementia|2013|386
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|333
Microfluidic-enhanced 3D bioprinting of aligned myoblast-laden hydrogels leads to functionally organized myofibers in vitro and in vivo
|Biomaterials|2017|330
Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study
|The Journal of Urology|2003|252